Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSP1(42)-FVO + MSP1(42)-3D7
- Development stage
- Phase 1
- Lead developer
- Malaria Vaccine Development Branch
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
MSP1(42)-FVO + MSP1(42)-3D7 is a combination vaccine targeting blood-stage Plasmodium falciparum parasites. It consists of two recombinant proteins representing the C-terminal 42-kDa region of merozoite surface protein 1 (MSP1(42)) corresponding to the two allelic forms present in FVO and 3D7 P. falciparum lines. These proteins are expressed in Escherichia coli, refolded, purified, and formulated on Alhydrogel (aluminum hydroxide). The vaccine aims to induce immune responses that cover the major antigenic polymorphisms of MSP1, a leading blood-stage malaria vaccine candidate.
- Other names
- MSP1(42)-C1
02
Targets
MSP1 (Merozoite surface protein 1)
Beyond the preview
Go deeper on MSP1(42)-FVO + MSP1(42)-3D7.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSP1(42)-FVO + MSP1(42)-3D7.